GARP Research Downgrades Cepheid (CPHD) to Neutral; Walking A Thin Line

GARP Research downgraded Cepheid (NASDAQ: CPHD) from Buy to Neutral.

Analyst, Alastair Mackay, said, "The company’s mainstay assays are increasing in volume, pipeline tests are advancing, and the installed base of GeneXpert systems continues to expand. However, the company is priced for perfection, in our opinion, and while the fundamental story continues improving, we think any misstep could bring about a strong technical correction."

For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.

Shares of Cepheid closed at $38.07 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UBS Downgrades Applus Services SA (APPS:SM) to Neutral
• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Loop Capital Downgrades BJ's Wholesale (BJ) to Hold